Patients taking antiPD-1 medication and those with AIN not linked with PD-1 showed a significant variation in the pattern of PD-L1 staining. In a different case study by Kevin Parza [19], a 73-year-old man with a complicated medical history, including metastatic uveal melanoma with liver metastases, stage 3A chronic renal disease, hypertension, type 2 diabetes, and hyperlipidemia, received his first dose of ipilimumab and underwent a liver biopsy three weeks before the diagnosis of acute tubulointerstitial nephritis (ATIN). This evidence concerns the gene PDCD1 and chronic kidney disease.